LUCD News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$99.3M

Volume

2.27M

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026Lucid Diagnostics Inc. (NASDAQ:LUCD), a cancer prevention medical diagnostics company and subsidiary of PAVmed Inc., announced it will host a business update conference call and webcast on March 26, 2026, at 8:30 AM ET. CEO Lishan Aklog will provide a business update and discuss operations and growth strategy, while CFO Dennis McGrath will discuss fourth quarter 2025 financial results.Benzinga · Mar 12, 2026

PAVmed Announces Reverse Stock SplitPAVmed Inc. announced a 1-for-30 reverse stock split effective January 2, 2026, to comply with Nasdaq's $1.00 minimum bid price requirement. The split was approved by stockholders on December 5, 2025, and authorized shares will be reduced from 250 million to 25 million. The company's stock will continue trading under symbol PAVM on Nasdaq Capital Market.Benzinga · Dec 30, 2025

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025Lucid Diagnostics will host a business update conference call on November 12, 2025, at 8:30 AM ET, where CEO Lishan Aklog will discuss company operations and growth strategy, and CFO Dennis McGrath will review Q3 2025 financial results.Benzinga · Oct 29, 2025

Lucid Diagnostics Announces Proposed Public Offering of Common StockLucid Diagnostics, a cancer prevention medical diagnostics company, announced plans for a public stock offering to support working capital and general corporate purposes, with Canaccord Genuity LLC and BTIG, LLC acting as joint bookrunners.Benzinga · Sep 9, 2025

PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024PAVmed, a diversified medical technology company, will host a business update conference call and webcast on November 14, 2024, to discuss its third quarter 2024 financial results and provide an overview of its operations and growth strategy.Benzinga · Oct 31, 2024

October's 4 Best Penny Stocks: High-Risk, High-Reward PicksThe article highlights four promising penny stocks with high-risk, high-reward potential: Allurion Technologies, Lucid Diagnostics, KULR Technology Group, and Gevo. These companies operate in diverse industries, including weight loss management, medical diagnostics, sustainable energy, and renewable fuels.Benzinga · Oct 9, 2024

Where Lucid Diagnostics Stands With AnalystsAnalysts have provided the following ratings for Lucid Diagnostics (NASDAQ:LUCD) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Lucid Diagnostics has an average price target of $3.0 with a high of $4.00 and a low of $2.60. Below is a summary of how these 4 analysts rated Lucid Diagnostics over the past 3 months. The greater the number of bullish ratings, the more ...Full story available on Benzinga.comBenzinga · May 17, 2023

10 Biggest Price Target Changes For TuesdayBTIG cut the price target on NeoGenomics, Inc. (NASDAQ: NEO) from $35 to $28. NeoGenomics shares fell 29.2% to $12.60 in pre-market trading. Craig-Hallum lowered Stryve Foods, Inc. (NASDAQ: SNAX) price target from $15 to $3. Stryve Foods shares fell 20.8% to $1.58 in pre-market trading. Citigroup cut the price target on XPeng Inc. (NYSE: XPEV) from $92 to $67. XPeng shares rose 1.6% to $27.57 in pre-market trading. Canaccord Genuity cut the price target for Sientra, Inc. ...Full story available on Benzinga.comBenzinga · Mar 29, 2022

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And MoreBiotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out to be negative for several others engaged in COVID-19 vaccine and treatment research. Pfizer announced Friday its oral COVID-19 pill Paxlovid reduced the risk of COVID-19-related hospitalization or death by 89%. Merck & Co., Inc. (MRK: NYSE), which also has a competing medication in the pipeline, shed close to 10% on Friday. Stocks also reacted to the earnings, which came in thick and fast during the week. Five stocks belonging to the biotech and diagnostics spaces, debuted on Wall Street during the week. Here are the key upcoming catalysts that biotech investors are on in the unfolding week: Health Care Conferences: American College of Rheumatology, or ACR, Convergence 2021: Nov. 3-9 (virtual) BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology: Nov. 8 (virtual event) Credit Suisse 30th Annual Virtual Healthcare Conference: Nov. 8-11 (virtual conference) 14th Clinical Trial On Alzheimer's Disease, or CTAD, 2021: Nov. 9-12 (in Boston) 6th Respiratory Syncytial Virus Network, or RESVINET, Conference: Nov. 10-12 (virtual meeting) Society For Immunotherapy of Cancer: Nov. 10-14 (hybrid event, to be held in Washington, D.C. and to be available virtually) Connective Tissue Oncology Society, or CTOS, 2021 Annual Meeting: Nov. 10-13 (virtual meeting) American Academy of Ophthalmology, or AAO, 2021 Meeting: Nov. 12-13 (in New Orleans) American Association for the Study of Liver Diseases, AASLD, The Liver Meeting 2021: Nov. 12-15 (virtual meeting) Clinical Readouts/Presentations Liver Meeting Presentations Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA): Phase 1b data for EDP-514 in viremic, chronic hepatitis B infected patients Vir Biotechnology, Inc. (NASDAQ: VIR): Preliminary results from a Phase 1 study evaluating a single dose of VIR-3434, a novel neutralizing, vaccinal monoclonal antibody, for hepatitis B infection (Friday, at 8 a.m.) Vaccitech plc (NASDAQ: VACC): Interim results of HBV001, a Phase 1 study evaluating therapeutic vaccination with ChAdOx1-HBV in healthy volunteers and patients with chronic hepatitis B infection; Phase 1b/2a study of heterologous ChAdOx1/MVA therapeutic vaccination combined with Bristol-Myers Squibb Company's (NYSE: BMY) low-dose Opdivo in virally-suppressed patients with CHB under nucleos(t)ide analogues Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA): results of a subpopulation pharmacokinetic and safety analysis from the Phase 1 trial of RG6346, which Dicerna is developing in collaboration with Roche Holding AG (OTC: RHHBY) for the treatment of chronic hepatitis B virus infection; interim Phase 1 data from Belcesiran in Alpha 1-antitrypsin deficiency-associated liver disease Lipocine Inc. (NASDAQ: LPCN): safety And tolerability Of LPCN 1144 treatment In biopsy confirmed NASH subjects from the Phase 2 LiFT study Arbutus Biopharma Corporation (NASDAQ: ABUS): data on the effects of its ...Benzinga · Nov 8, 2021

Wall Street Breakfast: The Week AheadListen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.Seeking Alpha · Nov 7, 2021

LUCDLucid Diagnostics Inc. Common Stock

LUCD

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any LUCD yet.

Related Tickers

Earnings

Volume

2.27M

Next Earnings

November 11th